Abstract
Most drug discovery efforts for Alzheimers disease (AD) have focused on prevention or clearance of β- amyloid (Aβ) fibrils or oligomers, with far less attention to prevention of τ abnormalities that lead to neurofibrillary tangles (NFTs). Much evidence now indicates that Ab multimers can trigger neurodegenerative changes that involve formation of dystrophic neurites and cytoskeletal collapse, possibly due loss of microtubule (MT) stabilization by the τ protein. We have found that several MT-stabilizing agents such as Taxol significantly enhanced neuronal survival in the presence of Aβ and identified agents that enter the brain, a necessity for in vivo testing in animal models of t pathology. Studies were designed to test two agents in the τ mutant (JNPL3) mouse that develops severe motor deficits at about seven months of age, accompanied by neuropathological markers of t pathology. In addition to using motor performance tests through the planned period of drug administration, we designed a simple appetitive memory test that required a reduction in ad lib food intake. Although the neurochemical data are still being analyzed, we were surprised to find that all of the JNPL3 mice, whether receiving the drug or not, developed no signs of motor impairment up to 10 months of age. This is considerably beyond the age at which free-fed mice survived and suggests that the food restriction alone may have delayed the pathological process. A study is ongoing with free-fed mice to determine if the drug interventions do have any beneficial effects in these mutant mice.
Keywords: neurodegeneration, AD-like mouse model, KU-237, JNPL3 mice, microtubule
Current Alzheimer Research
Title: Ongoing In Vivo Studies with Cytoskeletal Drugs in Tau Transgenic Mice
Volume: 3 Issue: 3
Author(s): Mary L. Michaelis
Affiliation:
Keywords: neurodegeneration, AD-like mouse model, KU-237, JNPL3 mice, microtubule
Abstract: Most drug discovery efforts for Alzheimers disease (AD) have focused on prevention or clearance of β- amyloid (Aβ) fibrils or oligomers, with far less attention to prevention of τ abnormalities that lead to neurofibrillary tangles (NFTs). Much evidence now indicates that Ab multimers can trigger neurodegenerative changes that involve formation of dystrophic neurites and cytoskeletal collapse, possibly due loss of microtubule (MT) stabilization by the τ protein. We have found that several MT-stabilizing agents such as Taxol significantly enhanced neuronal survival in the presence of Aβ and identified agents that enter the brain, a necessity for in vivo testing in animal models of t pathology. Studies were designed to test two agents in the τ mutant (JNPL3) mouse that develops severe motor deficits at about seven months of age, accompanied by neuropathological markers of t pathology. In addition to using motor performance tests through the planned period of drug administration, we designed a simple appetitive memory test that required a reduction in ad lib food intake. Although the neurochemical data are still being analyzed, we were surprised to find that all of the JNPL3 mice, whether receiving the drug or not, developed no signs of motor impairment up to 10 months of age. This is considerably beyond the age at which free-fed mice survived and suggests that the food restriction alone may have delayed the pathological process. A study is ongoing with free-fed mice to determine if the drug interventions do have any beneficial effects in these mutant mice.
Export Options
About this article
Cite this article as:
Michaelis L. Mary, Ongoing In Vivo Studies with Cytoskeletal Drugs in Tau Transgenic Mice, Current Alzheimer Research 2006; 3 (3) . https://dx.doi.org/10.2174/156720506777632880
DOI https://dx.doi.org/10.2174/156720506777632880 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Age-related Changes in Respiratory Function and Daily Living. A Tentative Model Including Psychosocial Variables, Respiratory Diseases and Cognition
Current Aging Science Methylenetetrahydrofolate Reductase: Biochemical Characterization and Medical Significance
Current Pharmaceutical Design Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Recombinant Tissue-Type Plasminogen Activator (Alteplase) in the Management of Acute Ischemic Stroke: A Review of its Pharmacological Properties, Efficacy, Safety and Pharmacoeconomic Aspects
Current Drug Therapy Applications of Artificial Neural Networks in Medical Science
Current Clinical Pharmacology Chronic Obstructive Pulmonary Disease and Asthma and the Risk of Mild Cognitive Impairment and Dementia: A Population Based CAIDE Study
Current Alzheimer Research Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration
Mini-Reviews in Medicinal Chemistry Human Cognition Assessment in Drug Research
Current Pharmaceutical Design The Key Role of Membranes in Amyloid Formation from a Biophysical Perspective
Current Protein & Peptide Science SPECT Radiopharmaceuticals for Dementia
Current Radiopharmaceuticals MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Mitochondrial Respiration in the Platelets of Patients with Alzheimer’s Disease
Current Alzheimer Research Patient Involvement and Shared Decision-Making in Mental Health Care
Current Clinical Pharmacology Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets Natural Anti-inflammatory Compounds as Drug Candidates in Alzheimer’s Disease
Current Medicinal Chemistry The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Cardiovascular Disease: Focus on Dyslipidemia (Executive Guest Editor: I. Gouni-Berthold)]
Current Pharmaceutical Design Sleep Apnea and Coronary Heart Disease: From Dusk Till Dawn and Further
Current Respiratory Medicine Reviews Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women
Mini-Reviews in Medicinal Chemistry Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry